<DOC>
	<DOCNO>NCT02597049</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know dulaglutide add sodium-glucose co-transporter 2 ( SGLT2 ) inhibitor participant type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Dulaglutide ( LY2189265 ) Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Have type 2 diabetes mellitus ( base World Health Organization 's [ WHO ] diagnostic criterion ) Have treat SGLT2 inhibitor , without metformin , least 3 month prior study entry ( minimum require dos period allow SGLT2 inhibitor : empagliflozin 10 mg , dapagliflozin 5 10 mg [ per countryspecific label ] , canagliflozin 100 mg ) ; minimum require dose metformin , use , ≥1500 mg/day must reach ( high tolerate dose acceptable document gastrointestinal [ GI ] intolerability ) Daily dose allow oral antihyperglycemia agent ( OAMs ) must stable least 12 week ( ±3 day ) prior randomization ( study enrollment ) ; daily dos SGLT2 inhibitor metformin , use , consider stable period : prescribed daily dos range minimum require dose maximumapproved dose per countryspecific label ; &gt; 90 % prescribed daily dos equal dose randomization Have HbA1c ≥7.0 % ≤9.5 % study entry approximately 1 week prior randomization Have body mass index ( BMI ) ≤45 kilogram per meter square ( kg/m^2 ) agree initiate diet and/or exercise program study intent reduce body weight lifestyle dietary measure diabetes treatment Have type 1 diabetes mellitus Have treat ANY OAMs ( SGLT2 inhibitor metformin ) , glucagonlike peptide1 receptor agonist ( GLP1 RA ) , pramlintide insulin 3 month prior study entry , study entry randomization ; initiate metformin study entry randomization ; shortterm use insulin acute care ( ≤14 day ) 3month period prior entry exclusionary Have condition contraindication use GLP1 RA class SGLT2 inhibitor class ( per countryspecific label ) study entry develop condition study entry randomization Have acute chronic hepatitis , sign symptoms liver disease nonalcoholic fatty liver disease ( NAFLD ) , alanine transaminase ( ALT ) level &gt; 2.5 time upper limit reference range , determined central laboratory study entry ; participant NAFLD eligible participation trial Had chronic acute pancreatitis time prior study entry Estimated glomerular filtration rate ( eGFR ) &lt; 45 milliliter ( mL ) /minute/1.73m^2 , calculate Chronic Kidney DiseaseEpidemiology ( CKDEPI ) equation , determined central laboratory study entry confirm lead Have self family history type 2A type 2B multiple endocrine neoplasia ( MEN 2A 2B ) absence know Ccell hyperplasia ( exclusion include participant family history MEN 2A 2B , whose family history syndrome rearrange transfect [ RET ] negative ; exception exclusion participant whose family member MEN 2A 2B know RET mutation potential participant study negative RET mutation ) Have self family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma ( include sporadic , familial , part MEN 2A 2B syndrome ) Have serum calcitonin ≥20 picograms/mL determine central laboratory study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>